Evotec stock gains modestly as short interest rises and shares hover near 52-week low

Published on 09/17/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock traded around EUR 2.83 on Xetra on September 17, 2026, only 2.33 percent above its 52-week low from September 15, 2026. Rising reported short positions add pressure while the company sharpens its profile at a major healthcare conference.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec SE stock (ISIN DE0005664809) was quoted at around EUR 2.83 on Xetra on September 17, 2026, leaving the biotech group only 2.33 percent above its 52-week low of EUR 2.77 reached on September 15, 2026, according to data from finanzen.ch.

Evotec stock edges higher despite short pressure

On September 17, 2026, Evotec shares gained about 0.9 percent in Xetra trading to EUR 2.83, after opening at EUR 2.82 and touching an intraday high of EUR 2.84, as reported by finanzen.ch.

According to finanzen.ch on September 17, 2026, the stock was trading at EUR 2.81 around midday, up 0.2 percent, and had set its 52-week low at EUR 2.77 on September 15, 2026, leaving only 1.71 percent downside to return to that low from the EUR 2.81 level.

Short positions build while the share price firms

Recent disclosures show that hedge funds have increased their short positions in Evotec in September 2026, adding a layer of pressure even as the stock attempts a modest recovery. According to Aktiencheck on September 16, 2026, Winton Capital Management Limited raised its net short position in Evotec from 0.52 percent to 0.61 percent of the share capital, an increase of 0.09 percentage points.

In the same analysis, Aktiencheck reports that Capital Ventures International held a net short position of 0.93 percent as of September 14, 2026, Y-Intercept (Hong Kong) Limited reported 0.51 percent from September 11, 2026, and Capital Fund Management SA also stood at 0.51 percent from September 4, 2026, bringing these four positions together to 2.56 percent of Evotec’s share capital.

Despite this aggregate short interest, the same article notes that Evotec stock was trading at EUR 2.842 on September 16, 2026, up 1.28 percent on the day, indicating that short sellers have recently faced a modest counter-move in the share price, even though the level remains close to the 52-week low.

Company presentation aims to clarify strategy

Beyond the trading dynamics, Evotec is working on sharpening its corporate profile for investors. As Investing.com reported on September 16, 2026, Evotec took part in the 24th Annual Global Healthcare Conference organized by Morgan Stanley to present its business model more clearly while the stock continues to trade near its 52-week low.

In parallel, a company presentation dated September 2026 is referenced in an EQS disclosure, which lists an Evotec SE presentation in English for that month, underscoring the group’s effort to communicate its strategy and key commercial metrics to the market, according to EQS.

The combination of active short interest and a share price that has hovered only a few percent above its 52-week low puts the spotlight on Evotec’s ability to execute its pipeline and contract research strategy, and makes communication at such investor conferences a significant factor for sentiment.

Stock remains tied to MDAX performance and liquidity

Evotec SE is listed on Xetra and belongs to the MDAX index, and recent trading data highlight both its liquidity and its weight in the small and mid-cap segment. According to a midday market overview from finanzen.ch on September 17, 2026, the Evotec share was the most-traded stock in the SDAX-related context at that time, with 203,844 shares changing hands via Xetra.

The same overview notes that the Evotec share dominated that index segment by market capitalization with a share of about EUR 4.185 billion as of the reporting moment, underlining that even at a share price near EUR 2.80 the company remains a significant player among German mid caps.

Another intraday snapshot from finanzen.ch shows that by 09:28 on September 17, 2026, 8,428 Evotec shares had been traded on Xetra at EUR 2.83, illustrating that the early session already saw meaningful liquidity.

Closing price and valuation signal for investors

Per Xetra data cited by finanzen.net and summarized in an article dated September 17, 2026, Evotec stock closed at EUR 2.81 on Xetra on September 16, 2026, representing a 2.43 percent gain compared with the previous close and signaling a tentative attempt to stabilize after hitting the 52-week low two days earlier.